



US009901585B2

(12) **United States Patent**
Lulla et al.

(10) **Patent No.:** **US 9,901,585 B2**
(45) **Date of Patent:** ***Feb. 27, 2018**

(54) **COMBINATION OF AZELASTINE AND FLUTICASONE FOR NASAL ADMINISTRATION**

(71) Applicant: **Cipla Limited**, Mumbai (IN)

(72) Inventors: **Amar Lulla**, Mumbai (IN); **Geena Malhotra**, Mumbai (IN)

(73) Assignee: **Cipla Limited**, Mumbai (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/070,839**

(22) Filed: **Mar. 15, 2016**

(65) **Prior Publication Data**
US 2017/0035780 A1 Feb. 9, 2017

Related U.S. Application Data

(60) Continuation of application No. 14/661,700, filed on Mar. 18, 2015, now abandoned, which is a continuation of application No. 14/539,646, filed on Nov. 12, 2014, now abandoned, which is a continuation of application No. 13/644,127, filed on Oct. 3, 2012, now Pat. No. 8,937,057, which is a continuation of application No. 12/508,388, filed on Jul. 23, 2009, now Pat. No. 8,318,709, which is a division of application No. 10/518,016, filed as application No. PCT/GB03/02557 on Jun. 13, 2003, now Pat. No. 8,168,620.

Foreign Application Priority Data

Jun. 14, 2002 (GB) 0213739.6

(51) **Int. Cl.**

- A61K 31/56** (2006.01)
- A61K 9/10** (2006.01)
- A61K 47/26** (2006.01)
- A61K 47/18** (2017.01)
- A61K 47/10** (2017.01)
- A61K 47/38** (2006.01)
- A61K 9/00** (2006.01)
- A61K 31/55** (2006.01)
- A61K 31/58** (2006.01)
- A61K 31/573** (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/56** (2013.01); **A61K 9/0043** (2013.01); **A61K 9/10** (2013.01); **A61K 31/55** (2013.01); **A61K 31/573** (2013.01); **A61K 31/58** (2013.01); **A61K 47/10** (2013.01); **A61K 47/183** (2013.01); **A61K 47/186** (2013.01); **A61K 47/26** (2013.01); **A61K 47/38** (2013.01)

(58) **Field of Classification Search**

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 2,837,464 A 6/1958 Nobile
- 3,067,197 A 12/1962 Agnello et al.
- 3,312,590 A 4/1967 Elks et al.
- 3,506,694 A 4/1970 Oxley
- 3,557,162 A 1/1971 Lens et al.
- 3,639,434 A 2/1972 Oxley et al.
- 3,755,302 A 8/1973 Ercoli et al.
- 3,813,384 A 5/1974 Vogelsang et al.
- 3,828,080 A 8/1974 Phillipps et al.
- 3,856,828 A 12/1974 Phillipps et al.
- 3,891,631 A 6/1975 Phillipps et al.
- 3,981,894 A 9/1976 Phillipps et al.
- 3,989,686 A 11/1976 Phillipps et al.
- 4,093,721 A 6/1978 Phillipps et al.
- 4,113,680 A 9/1978 Kamano et al.
- 4,187,301 A 2/1980 Edwards
- 4,188,385 A 2/1980 Edwards
- 4,198,403 A 4/1980 Alvarez
- 4,221,787 A 9/1980 Bodor et al.
- 4,261,984 A 4/1981 Alvarez
- 4,263,289 A 4/1981 Edwards
- 4,267,173 A 5/1981 Draper
- 4,285,937 A 8/1981 Kalvoda
- 4,310,466 A 1/1982 Edwards

(Continued)

FOREIGN PATENT DOCUMENTS

- AU 2003244799 B2 12/2003
- BE 889563 A1 11/1981

(Continued)

OTHER PUBLICATIONS

ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1999-2000, cover page, p. 43 and index p. 1882, Datapharm Publications Limited, London.
ABPI Data Sheet Compendium, 1995-96, cover page plus pp. 38-39, Datapharm Publications Limited, London.
Aigbirhio, Franklin I., et al., "Automated radiosynthesis of no-carrier-added [S-fluoromethyl-18F]Fluticasone propionate as a radiotracer for lung deposition studies with PET," Journal of Labelled Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp. 569-584, John Wiley & Sons, Ltd.
Akerlund, Anders, et al., "Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication," J. Allergy Clin Immunol, Mar. 2005, vol. 115, No. 3, pp. S460-S482.

(Continued)

Primary Examiner — Robert A Wax
Assistant Examiner — Thor Nielsen
(74) *Attorney, Agent, or Firm* — Conley Rose, P.C.; Rodney B. Carroll

(57) **ABSTRACT**

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

(56)

References Cited

U.S. PATENT DOCUMENTS

4,335,121 A 6/1982 Phillipps et al.
 4,377,575 A 3/1983 Stache et al.
 4,472,393 A 9/1984 Shapiro
 4,607,028 A 8/1986 Schmidlin
 4,710,495 A 12/1987 Bodor
 4,782,047 A 11/1988 Benjamin et al.
 4,861,765 A 8/1989 Mitsukuchi et al.
 4,992,474 A 2/1991 Skidmore et al.
 4,994,439 A 2/1991 Longenecker et al.
 4,996,335 A 2/1991 Bodor
 5,063,222 A 11/1991 Komoto et al.
 5,081,113 A 1/1992 Claussner et al.
 5,086,050 A 2/1992 Hettche et al.
 5,164,194 A 11/1992 Hettche
 5,202,316 A 4/1993 Claussner et al.
 5,232,919 A 8/1993 Scheffler et al.
 5,271,946 A 12/1993 Hettche
 5,362,721 A 11/1994 Stache et al.
 5,420,120 A 5/1995 Boltralik
 5,536,444 A 7/1996 Hettche et al.
 5,608,093 A 3/1997 Stache et al.
 5,658,549 A 8/1997 Akehurst et al.
 5,658,919 A 8/1997 Ratnaraj et al.
 5,707,984 A 1/1998 Tjoeng et al.
 5,716,966 A 2/1998 Cupps et al.
 5,830,490 A 11/1998 Weinstein et al.
 5,837,699 A 11/1998 Sequeira et al.
 5,849,265 A 12/1998 Li-Bovet et al.
 5,854,269 A 12/1998 Haslwanter et al.
 5,889,015 A 3/1999 Sequeira et al.
 5,897,858 A 4/1999 Haslwanter et al.
 5,914,122 A 6/1999 Otterbeck et al.
 5,972,327 A 10/1999 Lin et al.
 5,972,920 A 10/1999 Seidel
 5,976,573 A 11/1999 Kim
 5,981,517 A 11/1999 Bodor
 5,993,781 A 11/1999 Snell et al.
 6,017,963 A * 1/2000 Alfonso A61K 9/0043
 514/646
 6,057,307 A 5/2000 Sequeira et al.
 6,127,353 A 10/2000 Yuen et al.
 6,136,294 A 10/2000 Adjei et al.
 6,143,329 A 11/2000 Kim
 6,197,761 B1 3/2001 Biggadike et al.
 6,241,969 B1 6/2001 Saidi et al.
 6,253,762 B1 7/2001 Britto
 6,261,539 B1 7/2001 Adjei et al.
 6,294,153 B1 * 9/2001 Modi A61K 9/006
 424/130.1
 6,316,483 B1 11/2001 Haslwanter et al.
 6,319,513 B1 11/2001 Dobrozsi
 6,330,938 B1 12/2001 Hervé et al.
 6,368,616 B1 4/2002 Doi
 6,391,340 B1 * 5/2002 Malmqvist-Granlund
 A61K 9/0043
 424/434
 6,395,300 B1 5/2002 Straub et al.
 6,416,743 B1 7/2002 Fassberg et al.
 6,436,924 B2 8/2002 Poppe et al.
 6,537,983 B1 3/2003 Biggadike et al.
 6,565,832 B1 5/2003 Haslwanter et al.
 6,583,180 B2 6/2003 Link et al.
 6,750,210 B2 6/2004 Biggadike
 6,759,398 B2 7/2004 Biggadike
 6,777,399 B2 8/2004 Biggadike et al.
 6,777,400 B2 8/2004 Biggadike et al.
 6,787,532 B2 9/2004 Biggadike et al.
 6,835,724 B2 12/2004 Stache et al.
 6,858,593 B2 2/2005 Biggadike et al.
 6,858,596 B2 2/2005 Biggadike et al.
 6,878,698 B2 4/2005 Biggadike et al.
 6,881,423 B2 4/2005 Dohi et al.
 6,921,757 B2 7/2005 Cuenoud et al.

7,132,532 B2 11/2006 Biggadike et al.
 7,144,845 B2 12/2006 Biggadike et al.
 7,214,672 B2 5/2007 Komoto et al.
 7,244,742 B2 7/2007 Pieper et al.
 7,288,536 B2 10/2007 Biggadike et al.
 7,291,608 B2 11/2007 Biggadike et al.
 7,291,609 B2 11/2007 Biggadike et al.
 7,405,206 B2 7/2008 Biggadike et al.
 7,498,321 B2 3/2009 Biggadike et al.
 7,524,970 B2 4/2009 John
 7,531,528 B2 5/2009 Biggadike et al.
 7,541,350 B2 6/2009 Biggadike et al.
 7,579,335 B2 8/2009 Biggadike et al.
 7,592,329 B2 9/2009 Biggadike et al.
 7,629,335 B2 12/2009 Biggadike et al.
 7,638,508 B2 12/2009 Biggadike et al.
 7,776,315 B2 8/2010 Pairet et al.
 8,071,073 B2 12/2011 Dang et al.
 8,163,723 B2 4/2012 Lulla et al.
 8,168,620 B2 5/2012 Lulla et al.
 8,304,405 B2 11/2012 Lulla et al.
 8,318,709 B2 11/2012 Lulla et al.
 8,933,060 B2 1/2015 Lulla et al.
 8,937,057 B2 1/2015 Lulla et al.
 9,259,428 B2 2/2016 Lulla et al.
 2001/0025040 A1 9/2001 Poppe et al.
 2002/0037297 A1 3/2002 Crespo et al.
 2002/0061281 A1 5/2002 Osbakken et al.
 2002/0076382 A1 6/2002 Kaplan et al.
 2002/0081266 A1 6/2002 Woolfe et al.
 2002/0132803 A1 9/2002 Dedhiya et al.
 2003/0018019 A1 1/2003 Meade et al.
 2004/0136918 A1 7/2004 Garrett et al.
 2004/0204399 A1 10/2004 Osbakken et al.
 2004/0235807 A1 11/2004 Weinrich et al.
 2004/0242638 A1 12/2004 Yanni et al.
 2005/0163724 A1 7/2005 Miyadai et al.
 2005/0192261 A1 9/2005 Jost-Price et al.
 2006/0002861 A1 1/2006 Biggadike
 2006/0228306 A1 10/2006 Lane
 2007/0020330 A1 1/2007 Dang et al.
 2009/0124585 A1 5/2009 Cross et al.
 2009/0156567 A1 6/2009 Biggadike
 2009/0286762 A1 11/2009 Myles et al.
 2010/0152147 A1 6/2010 Fuge et al.
 2010/0311706 A1 12/2010 Biggadike et al.
 2012/0065177 A1 3/2012 Myles et al.
 2015/0072010 A1 3/2015 Lulla et al.

FOREIGN PATENT DOCUMENTS

DE 1059906 B 6/1959
 DE 2164058 A1 7/1972
 DE 3836579 A1 5/1989
 DE 19947234 A1 4/2001
 DE 10152369 A1 5/2002
 EP 0004773 A2 10/1979
 EP 0057401 A1 8/1982
 EP 0179583 A1 4/1986
 EP 0393658 B1 10/1990
 EP 0416951 A1 3/1991
 EP 0780127 A1 * 6/1997 A61K 31/57
 EP 1519731 B1 4/2009
 EP 2072051 A1 6/2009
 EP 2075000 A1 7/2009
 GB 1191965 5/1970
 GB 1296458 11/1972
 GB 1384372 2/1975
 GB 1438940 6/1976
 GB 1517278 7/1978
 GB 2079755 A 1/1982
 GB 2088877 A 6/1982
 GB 2140800 A 12/1984
 GB 2389530 A 12/2003
 IL 109656 A 2/1998
 JP 4208267 A 7/1992
 JP 8291072 A 11/1996

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	8504589	A1	10/1985
WO	8903390	A1	4/1989
WO	9015816	A1	12/1990
WO	9104252	A1	4/1991
WO	9214472	A1	9/1992
WO	9408551	A2	4/1994
WO	9531964	A1	11/1995
WO	9619199	A1	6/1996
WO	9619969	A1	7/1996
WO	9632151	A1	10/1996
WO	9701337	A1	1/1997
WO	9705136	A1	2/1997
WO	9715298	A1	5/1997
WO	9721721	A1	6/1997
WO	9721724	A1	6/1997
WO	9724365	A1	7/1997
WO	9731626	A1	9/1997
WO	9740836	A1	11/1997
WO	9746243	A1	12/1997
WO	9817676	A1	4/1998
WO	9824450	A1	6/1998
WO	9834596	A2	8/1998
WO	9848839	A1	11/1998
WO	9901467	A2	1/1999
WO	9925359	A1	5/1999
WO	9932089	A1	7/1999
WO	0016814	A1	3/2000
WO	0027373	A1	5/2000
WO	0033892	A1	6/2000
WO	0038811	A1	7/2000
WO	0041816	A1	7/2000
WO	0048587	A1	8/2000
WO	0049993	A2	8/2000
WO	0066522	A1	11/2000
WO	0104118	A2	1/2001
WO	01020331	A1	3/2001
WO	0122955	A2	4/2001
WO	0154481	A2	8/2001
WO	0154664	A1	8/2001
WO	0157025	A1	8/2001
WO	0162722	A2	8/2001
WO	0178736	A1	10/2001
WO	0178739	A1	10/2001
WO	0178741	A1	10/2001
WO	0178745	A1	10/2001
WO	0200199	A1	1/2002
WO	0200679	A2	1/2002
WO	0202565	A2	1/2002
WO	0207767	A2	1/2002
WO	0208243	A1	1/2002
WO	0211711	A2	2/2002
WO	0212265	A1	2/2002
WO	0212266	A1	2/2002
WO	0213868	A1	2/2002
WO	0226723	A1	4/2002
WO	0236106	A2	5/2002
WO	02051422	A1	7/2002
WO	02053186	A2	7/2002
WO	02066422	A1	8/2002
WO	02070490	A1	9/2002
WO	02076933	A1	10/2002
WO	02085296	A2	10/2002
WO	02088167	A1	11/2002
WO	02100879	A1	12/2002
WO	03000241	A2	1/2003
WO	03013427	A2	2/2003
WO	03033000	A1	4/2003
WO	03035668	A2	5/2003
WO	03040691	A2	5/2003
WO	03042229	A1	5/2003
WO	03042230	A1	5/2003
WO	03048181	A1	6/2003
WO	03062259	A2	7/2003

WO	03066036	A1	8/2003
WO	03066656	A1	8/2003
WO	03072592	A1	9/2003
WO	03086399	A1	10/2003
WO	03105856	A1	12/2003
WO	2004013156	A1	2/2004
WO	2004019955	A1	3/2004
WO	2005005451	A1	1/2005
WO	2005005452	A1	1/2005
WO	2006058022	A1	6/2006
WO	2007061454	A1	5/2007
WO	2008012338	A2	1/2008
WO	2008012338	A3	1/2008
ZA	872389		4/1987

OTHER PUBLICATIONS

Applicant response to foreign communication European Patent 1519731, dated Aug. 11, 2011, 252 pages.

Applicants' response dated Feb. 24, (2010) 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Applicants' response dated Jun. 22, 2011 (9 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Applicants' response dated Oct. 6, 2010 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Applicants' response dated Sep. 6, 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Applicant response to foreign communication—CA 2489427, dated Dec. 20, 2010, 10 pages.

Applicant response to foreign communication—EP 03738280.1 (EP Patent 1519731), dated Sep. 6, 2010, 15 pages.

Applicant response to foreign communication—EP 03738280.1, dated Jan. 18, 2008, 14 pages.

Applicant response to foreign communication—EP 03738280.1, dated May 22, 2006, 36 pages.

Applicant response to foreign communication—KR 10-2004-7020819, dated Dec. 27, 2010, 18 pages.

Astelin® (azelastine hydrochloride) Nasal Spray, Physicians' Desk Reference, 2002, pp. 3339-3340 plus one page Product Information, Wallace Laboratories.

Astelin (azelastine hydrochloride) Nasal Spray, 2006, U.S. Physicians Desk Reference, pp. 1876-1877 plus cover page, MedPointe Pharmaceuticals.

Astepro (azelastine HCl) Nasal Spray 0.15%, Meda Pharmaceuticals Inc., Sep. 2, 2009, Press Release, pp. 1-4.

Aurora, Jack, "Nasal Delivery; Development of Nasal Delivery Systems: A Review," Drug Delivery Technology, vol. 2, No. 7, Oct. 2002, 8 pages, <http://www.drugdeliverytech.com/ME2/Segments/Publications:Article&id=9EB19EB2F29F462089CE081473F5F3CA>.

Austin, R.J.H., et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," European Respiratory Journal, 2002, vol. 20, pp. 1386-1392.

Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcellulose Sodium, NF Dispersion Cellulose, BP, Specifications and Analytical Methods, RC-16 Updated Oct. 1995 (Feb. 1999), 6 pages, FMC Corporation.

Azelastine, STN Registry No. 58581-89-8, STN Registry File, Retrieved Nov. 23, 2010, 1 page.

Baena-Cagnani, Carlos E., "Safety and Tolerability of Treatments for Allergic Rhinitis in Children," Drug Safety, 2004, vol. 27, No. 12, pp. 883-898, ADIS Data Information BV.

Banov, Charles H., et al., "Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis," Annals of Allergy, Sep. 1994, vol. 73, pp. 240-246.

Barnes, M. L., et al., "Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis," Clinical and Experimental Allergy, 2006, vol. 36, pp. 676-684, Blackwell Publishing Ltd.

Barnes, Peter J., "Chronic obstructive pulmonary disease: new opportunities for drug development," TiPS, vol. 19, Oct. 1998, pp. 415-423, Elsevier Science Ltd.

Barnes, Peter J., "Efficacy of inhaled corticosteroids in asthma," The

(56)

References Cited

OTHER PUBLICATIONS

Barnes, Peter J., "Novel approaches and targets for treatment of chronic obstructive pulmonary disease," *American Journal of Respiratory and Critical Care Medicine*, vol. 160, 1999, pp. S72-S79.

Baumgarten, C., et al., "Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 µg) combination product (SAS 40023)," *European Journal of Medical Research*, Jan. 29, 2002, vol. 7, pp. 1-7, I. Holzapfel Publishers.

Berge, Stephen M., et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Sciences*, vol. 66, No. 1, Jan. 1977, pp. 1-19.

Berstein, D. I., et al., "Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis," *Clinical and Experimental Allergy*, 2004, vol. 34, pp. 952-957, Blackwell Publishing Ltd.

Biggadike, Keith, "Fluticasone furoate/fluticasone propionate—different drugs with different properties," Letter to the Editor, *The Clinical Respiratory Journal*, pp. 183-184, 2011, Blackwell Publishing Ltd.

Block, John H., et al., "Inorganic Medicinal and Pharmaceutical Chemistry," 1986, cover, publication, and preface pages plus p. 100, Indian Edition, Varghese Publishing House, Bombay, India.

Bowler, Simon, "Long acting beta agonists," *Australian Family Physician*, vol. 27, No. 12, Dec. 1998, pp. 1115, 1117-1118.

Brooks, Carter D., et al., "Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination," *American Journal of Rhinology*, May-Jun. 1996, vol. 10, No. 3, pp. 193-199.

Bryson, Harriet M., et al., "Intranasal fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis," *Drugs*, 1992, vol. 43, No. 5, pp. 760-775, Adis International Limited.

Busse, William, et al., "Steroid-sparing effects of fluticasone propionate 100 µg and salmeterol 50 µg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 µg administered twice daily," *J Allergy Clin Immunol*, vol. 111, No. 1, Jan. 2003, pp. 57-65, Mosby, Inc.

Busse, William W., et al., "Corticosteroid-sparing effect of azelastine in the management of bronchial asthma," XP-000604179, *American Journal of Respiratory and Critical Care Medicine*, 1996, pp. 122-127, vol. 153.

CAS Registry No. 102113-40-6, 2004, 1 page, ACS on STN.

CAS Registry No. 90566-53-3, "Fluticasone," Entered STN: Nov. 16, 1984, 1 page, © 2008 ACS on STN.

Chapman, Richard W., et al., "Anti-inflammatory activity of inhaled mometasone furoate in allergic mice," *Arzneim.-Forsch./Drug Res.*, 1998, vol. 48, No. 4, pp. 384-391.

CIPLA Annual Report Extract, 2010 (report shows that they launched an FF+azelastine product in 2010), 103 pages.

Cipla Sixty-Ninth Annual Report 2004-2005, cover pages, information page, plus pp. 3, 5, and 44.

CIPLA's response to Statement of Opposition for EP1519731, 11 pages, 2002.

Comparative data of azelastine with steroids, 2011, 4 pages.

Daley-Yates, Peter T., et al., "Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations," *Br J Clin Pharmacol.*, 2001, vol. 51, pp. 103-105, Blackwell Science Ltd.

Declaration of Geena Malhotra for EP1519731 dated Aug. 11, 2011, 4 pages.

Declaration of Joachim Maus for EP1519731 dated Aug. 10, 2011, 6 pages.

Derby, Laura, et al., "Risk of cataract among users of intranasal corticosteroids," *J Allergy Clin Immunol*, 2000, vol. 105, No. 5, pp. 912-916, Mosby, Inc.

Dewester, Jeffrey, et al., "The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal

Dictionary of Organic Compounds, definition of "fluticasone," Sixth Edition, 1996, vol. 1, p. 3234 plus cover and publishing pages, Chapman & Hall.

Di Lorenzo, G., et al., "Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis," *Clinical and Experimental Allergy*, 2004, vol. 34, pp. 259-267, Blackwell Publishing Ltd.

Dolovich, Jerry, et al., "Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis," *Annals of Allergy*, Aug. 1994, vol. 73, pp. 147-153.

Notice of Allowance dated Nov. 18, 2015 (29 pages), U.S. Appl. No. 14/661,720, filed Mar. 18, 2015.

Duonase Data Sheet, "The Complete Rhinitis Control," 6 pages, Cipla Limited, Mumbai, India, 2002.

Dykewicz, Mark S., et al., "Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology," *Annals of Allergy, Asthma, & Immunology*, vol. 81, Nov. 1998 (Part II), pp. 478-518.

File history of Australian Patent Application No. AU2003244799, 38 pages.

File history of Brazilian Patent Application No. PI 0312128-3, 27 pages, 2002.

File history of Canadian Patent Application No. 2,489,427, 19 pages, 2002.

File history of Korean Patent Application No. 10-2004-7020819, 89 pages.

File history of Mexican Patent Application No. PA/a/2004/01266 (now Patent No. 265349), 86 pages.

File history of Polish Patent Application No. P-373001, 95 pages, dated May 2011, 2002.

File history of Russian Patent Application No. RU 2361593 C2, 65 pages, dated Apr. 2009.

File history of South African Patent Application No. 2005/0331 (now Patent No. 2005/0331), 18 pages.

Fluticasone Furoate, STN Registry No. 397864-44-7, Entered STN: Mar. 4, 2002, 1 page, © 2010 ACS on STN.

Foreign communication from a related counterpart application—Australian Application No. 2003244799, Examination Report, dated Nov. 20, 2007, 2 pages.

Foreign communication from a related counterpart application—Canadian Application No. 2,489,427, Examination Report, dated Jun. 18, 2010, 3 pages.

Foreign communication from a related counterpart application—Canadian Application No. 2,489,427, Examination Report, dated Mar. 24, 2011, 2 pages.

Foreign communication from a related counterpart application—Examination Report, European Application No. 03738280.1, dated Jul. 18, 2007, 5 pages.

Foreign communication from a related counterpart application—Examination Report, European Application No. 03738280.1, dated Nov. 10, 2005, 4 pages.

Foreign communication from a related counterpart application—European Application No. 03738280.1, Notice of Intent to Grant, dated Oct. 23, 2008, 6 pages.

Foreign communication from a related counterpart application—Examination Report, Russian Application No. 2005100781, dated Apr. 23, 2007, 6 pages.

Foreign communication from a related counterpart application—Examination Report, Russian Application No. 2005100781, dated May 23, 2008, 3 pages.

Foreign communication from a related counterpart application—Korean Application No. 10-2004-7020819, Examination Report, dated Aug. 26, 2010, 8 pages.

Foreign communication from a related counterpart application—Notice of Opposition, European Application No. 03738280.1, dated Feb. 22, 2010, 22 pages.

Foreign communication from a related counterpart application—Summons to Attend Oral Proceedings, European Application No. 03738280.1, dated Feb. 8, 2011, 1 page.

Foreign communication from a related counterpart application—

(56)

References Cited

OTHER PUBLICATIONS

Foreign communication from the priority application—International Preliminary Examination Report, PCT/GB03/02557, dated Aug. 26, 2004, 6 pages.

Foreign communication from the priority application—International Search Report, PCT/GB03/02557, dated Sep. 17, 2003, 3 pages.

Foreign communication from the priority application—Search Report, Great Britain Application No. 0213739.6, dated Nov. 22, 2002, 4 pages.

Foreign communication from a related counterpart application—First Examination Report, Indian Application No. 1696/MUMNP/2009, dated Jun. 27, 2012, 2 pages.

Foreign communication from a related counterpart application—First Examination Report, Indian Application No. 1695/MUMNP/2009, dated Jun. 29, 2012, 2 pages.

Foreign communication from a related counterpart application—Final Office Action, Korean Application No. 10-2011-7022532, dated Aug. 24, 2012, 6 pages.

Foreign communication from a related counterpart application—Final Office Action, Korean Application No. 10-2011-7022533, dated Aug. 24, 2012, 6 pages.

Foreign communication from a related counterpart application—Office Action, European Application No. 09075100.9, dated Aug. 8, 2012, 6 pages.

Foreign communication from a related counterpart application—EPO Communication, European Application No. 09075101.7, dated Aug. 8, 2012, 5 pages.

Fowler, Stephen J., et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone," *J Allergy Clin Immunol*, vol. 109, No. 6, Jun. 2002, pp. 929-935, Mosby, Inc.

Galant, Stanley P., et al., "Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child; What are the Options?," *BioDrugs*, 2001, vol. 15, No. 7, pp. 453-463, ADIS International Limited.

Garner, R. C., et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴C-labelled drugs in plasma, urine and faecal extracts," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 24, 2000, pp. 197-209, Elsevier Science B.V.

Gawchik, Sandra M., et al., "Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis," *The American Journal of Managed Care*, Jul. 1997, vol. 3, No. 7, pp. 1052-1058.

Gennaro, Alfonso R., et al., *Remington: The Science and Practice of Pharmacy*, 2000, 20th edition, vol. 1, pp. 785, 830, 831 plus cover page and publication pages, Lippincott Williams & Wilkins, a Walters Kluwer Company.

Gilbert, Peter, et al., "Preservation of Pharmaceutical Products," *Encyclopedia of Pharmaceutical Technology*, 2002, 2nd edition, vol. 3, p. 2278 plus cover page and publication pages, Marcel Dekker, Inc.

Hampel, Frank C., et al., "Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device," *Annals of Allergy, Asthma & Immunology*, vol. 105, pp. 168-173, Aug. 2010, American College of Allergy, Asthma & Immunology.

Harding, S. M., "The human pharmacology of fluticasone propionate," *Respiratory Medicine*, 1990, vol. 84, Suppl. A, pp. 25-29, Baillière Tindall.

Herrero, Vanrell R., "Preservatives in Ophthalmic Formulations: An Overview," *Arch Soc Esp Ophthalmol*, 2007, vol. 82, pp. 531-532.

Hodges, N. A., et al., "Preservative Efficacy Tests in Formulated Nasal Products: Reproducibility and Factors Affecting Preservative Activity," *J. Pharm. Pharmacol.*, 1996, vol. 48, pp. 1237-1242.

Hodges, Norman, et al., "Antimicrobial Preservative Efficacy Testing," *Handbook of Microbiological Quality Control, Pharmaceuticals and Medical Devices*, 2000, p. 168 plus cover page and

Holgate, Stephen T., et al., "Difficult Asthma," 1999, cover page and publishing information, Martin Dunitz Ltd.

Howarth, P. H., "A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis," *Allergy* 2000, vol. 62, pp. 6-11, Munksgaard 2000.

Howland, III, W. C., "Fluticasone propionate: topical or systemic effects?" *Clinical and Experimental Allergy*, 1996, vol. 26, Suppl. 3, pp. 18-22, Blackwell Science Ltd.

Isogai, Mitsutaka, et al., "Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue," *J. Steroid Biochem. Molec. Biol.*, 1993, vol. 44, No. 2, pp. 141-145, Peragom Press Ltd.

Flonase Nasal Spray, 0.05% w/w Product Information, 8 pgs., Sep. 1994, Allen & Hanburys, Division of Glaxo Inc.

FLOVENT Prescribing Information, GlaxoSmithKline, 19 pgs, 2002.

FLOVENT Rotadisk Prescribing Information, GlaxoSmithKline, 21 pgs, 2002.

Foreign communication from a related counterpart application—Communication of a Notice of Opposition, European Application No. 09075101.7, dated Nov. 5, 2014, 27 pages.

Foreign communication from a related counterpart application—Communication of Further Notices of Opposition, European Application No. 09075101.7, dated Dec. 5, 2014, 95 pages.

Giede, C., et al., "Comparison of Azelastine Eye Drops with Levocabastine Eye Drops in the Treatment of Seasonal Allergic Conjunctivitis," *Current Medical Research and Opinion*, 2000, pp. 153-163, vol. 16, No. 3, LibraPharm Limited.

Lee, et al., "How to treat allergic rhinitis," *Medicine Cabinet, WJM Western J. of Med.*, Jul. 1999, pp. 31-34, vol. 171.

Mabry, R.L., "Recent advances in pharmacotherapy of allergic rhinitis," *Current Opinion in Otolaryngology & Head and Neck Surgery* 1999, pp. 375-378 vol. 7, No. 6.

Office Action dated Oct. 17, 2008 (28 pages), U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.

Astelin Nasal Spray, Sep. 29, 1997, Package Insert.
Advair™ Diskus®, Final Printed Labeling, Center for Drug Evaluation and Research, Aug. 2000, 42 pages, GlaxoWellcome Inc.
Advair™ Diskus®, Printed Labeling, Revised: Apr. 2008, 62 pages, GlaxoSmithKline.

Aistars, Arnis, "Optimizing Antimicrobial Preservative Selection for Pharmaceutical Products," *Spectrum Excipients Bulletin*, Dec. 2011, 5 pages.

Backhouse, C. I., et al., "Treatment of Seasonal Allergic Rhinitis with Flunisolide and Terfenadine," *J. Int. Med. Res.*, 1986, vol. 14, No. 1, pp. 35-41 plus cover page.

Banker, Gilbert S., et al., "Modern Pharmaceutics," 4th ed., 2002, 3 pages, Marcel Dekker, Inc.

Davies, Robert J., et al., "Once-Daily Mometasone Furoate Nasal Spray: Efficacy and Safety of a New Intranasal Glucocorticoid for Allergic Rhinitis," *Clinical Therapeutics*, 1997, pp. 27-38, vol. 19, No. 1.

Falser, Norbert, et al., "Comparative Efficacy and Safety of Azelastine and Levocabastine Nasal Sprays in Patients with Seasonal Allergic Rhinitis," *Arzneim.-Forsch./Drug Res.*, 2001, pp. 387-393, vol. 51, No. 1, ECV (Editio Cantor Verlag), Germany.

Flonase® (fluticasone propionate) Nasal Spray, 50 mcg, Final Printed Labeling, Center for Drug Evaluation and Research, 1998, 13 pages, GlaxoWellcome Inc.

Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma," http://www.medscape.com/viewarticle/406237_print, [Clin Drug Invest, vol. 21, No. 9, 2001, pp. 633-642], Adis International Limited.

Johnson, Malcom, "Development of fluticasone propionate and comparison with other inhaled corticosteroids," *J Allergy Clin Immunol*, Apr. 1998, vol. 101, No. 4, Part 2, pp. S434-S439, Mosby, Inc.

Juniper, E. F., et al., "Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the pro-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.